2006年10月3日
碧萝芷®可改善糖尿病微血管病
Pycnogenol® Reduces Diabetic Microangiopathy

        实验表明血流速度可提高68%
        Study Reveals 68 Percent Improvement of Blood Flow

        糖尿病微血管疾病与许多糖尿病并发症密切相关，如腿部溃疡、肾功能衰退和视网膜疾病。医生通常会强制要求糖尿病患者接受完善的治疗来控制微血管疾病的病情。一项发表在《血管学》杂志9月版上的文章证实，碧萝芷®，法国沿海松树树皮提取物，可以大幅改善糖尿病微血管疾病。
        Diabetic microangiopathy is responsible for major diabetic health complications, such as leg ulcers, kidney failure and retinopathy. It is imperative diabetics receive the best treatment to manage this condition. A study published in the September edition of Angiology shows that Pycnogenol? (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, significantly reduced diabetic microangiopathy (DM) in patients after supplementing with Pycnogenol®.

        “糖尿病为血管疾病的症状非常常见并且会影响到每一位糖尿病患者。这一疾病可以导致失去视力的糖尿病性视网膜疾病、肾脏疾病、和身体组织缺血性坏死所引发的腿部溃疡。治疗腿部溃疡的常用手段就是通过截肢将坏死部分切除。” 此次实验的负责人Gianni Belcaro博士说，“患有糖尿病微血管病的病人的小血管（毛细血管）的血管壁非常脆弱，会发生渗血和蛋白质渗出，这些现象会影响并减慢血液的流动速度，进而会在血液中形成血块并引起肢体的肿胀（水肿）。”
        “Diabetic microangiopathy is not a rare phenomenon and essentially affects every diabetic person. The condition may result in vision loss in diabetic retinopathy, kidney problems and ischemic tissue necrosis causing leg ulcers which may lead to amputation,” said Dr. Gianni Belcaro, a lead researcher of the study. “With DM, the walls of very small blood vessels (capillaries) become so weak, bleeding and protein leaks occur, which ultimately slows down blood flow, resulting in blood clots and swelling of the limbs (edema).”

        这项在意大利Chieti-Pescara大学完成的实验有60名糖尿病人参与，这些病人均有3年以上胰岛素治疗的经历。实验过程中，要求病人在接受正常胰岛素治疗同时连续一个月每日口服150毫克碧萝芷®。同时，占受实验者人数50%的被分入实验对照组的病人接受安慰剂治疗。实验采用laser Doppler对病人的血液流动情况进行测量。
        The study sampled 60 diabetic patients suffering from DM being treated with insulin for at least three years at the Chieti-Pescara University in Italy. In addition to their insulin treatment, patients received 150 mg of Pycnogenol® orally daily for one month. The control group, 50 percent of the sample, received a placebo. Measurements of blood flow were measured by laser Doppler.

        在病人平躺和站立时均对病人进行血流速度检测。由于病人所患的糖尿病微血管疾病的影响，病人的毛细血管基本上丧失了对从平躺到站立过程中血压增加的适应调节能力。
        Measurements were taken when patients were lying down and standing up. The capillary adaptation to increased pressure from lying down to standing is generally impaired, due to vessel failure and increase of pressure in capillaries for individuals who suffer from DM.

        实验结果表明，当病人平躺时，碧萝芷®组病人的的血流速度提高了37%，而安慰剂组仅提高了4.7%。当在病人站立状态进行血流速度测量时，碧萝芷®组病人毛细血管的血流速度提高了68%，而安慰剂组仅提高了8%。
        Results showed that when patients were lying down, Pycnogenol® treatment improved capillary blood flow by 34 percent, compared to 4.7 percent in the placebo group. When patient’s blood flow was measured in a standing position, Pycnogenol® treatment improved capillary blood flow by 68 percent, compared to 8 percent in the placebo group.

        毛细血管的渗漏情况通过测量患者的踝关节水肿情况进行观察，踝关节水肿在病人从平躺到直立后的10分钟即可表现出来。经过碧萝芷®治疗的患者的水肿减轻了17%，同时测量得出，安慰剂组仅减轻了2.6%。
        Capillary leakage was recorded by measuring ankle swelling, which develops ten minutes after passing from lying down to standing up. After Pycnogenol® treatment, swelling was 17 percent lower, compared to 2.6 percent in the placebo group.

        “碧萝芷®能够在短短的4周之内大幅改善病人的微循环，这是在令人惊奇。” Gianni Belcaro博士如是说。Gianni Belcaro博士之前曾参与了大量的有关碧萝芷®对糖尿病作用效果的相关实验。
        “The rapid improvement of microvessel complication with Pycnogenol® in just four weeks is clinically remarkable,” said Dr. Belcaro, who has been a large part of previous Pycnogenol® and diabetes related studies.

        在7月份曾有一篇发表文章报道了碧萝芷®治疗糖尿病患者足部溃疡的功效。实验结果表明，病人通过口服或者局部涂抹碧萝芷®进行治疗，其足部溃疡的面积最多减小了75%。更早些的多项实验也证实了碧萝芷®超强的预防糖尿病视网膜疾病效果、降低血糖水平效果以及改善患有II型糖尿病患者的血管健康状况的功效。这些实验均可在碧萝芷®网站www.pycnogenol.com上找到。
        In July, a study was published supporting diabetic foot ulcer treatment with Pycnogenol®. Results revealed almost 75 percent decrease is ulcer size in patients who supplemented with both oral and local Pycnogenol®. Previous research supports Pycnogenol® treatment to be highly effective for prevention of diabetic retinopathy and to be effective in lowering glucose levels and increasing the health of blood vessels in patients with type II diabetes. Previous research may be found at www.pycnogenol.com. 。